Aerie Pharmaceuticals is a commercial-stage company focused on the development and commercialization of eye disease therapies including glaucoma and other eye-diseases.'In 2017, Aerie received FDA approval for its lead drug, Rhopressa, for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa is a once-daily formulation for IOP in patients suffering from open-angle glaucoma and ocular hypertension. The FDA also approved Rocklatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Glaucoma is one of the largest segments in the global ophthalmic market.'In addition, the company is developing sustained-release implants focused on retinal indications. These include AR-13503 (Rho kinase and Protein kinase C inhibitor implant) for macular edema due to retinal vein occlusion(RVO) and AR-1105 (dexamethasone steroid implant) for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).'...
+See More2025-06-21 05:25:00 Saturday ET
President Trump refreshes American fiscal fears, worries, and concerns through the One Big Beautiful Bill Act. The Congressional Budget Office (CBO) estimat
2026-02-02 12:30:00 Monday ET
With U.S. fintech patent approval, accreditation, and protection for 20 years, our proprietary alpha investment model outperforms most stock market indexes
2018-03-23 08:26:00 Friday ET
Personal finance and investment author Thomas Corley studies and shares the rich habits of self-made millionaires. Corley has spent 5 years studying the dai
2019-11-26 11:30:00 Tuesday ET
AYA Analytica finbuzz podcast channel on YouTube November 2019 In this podcast, we discuss several topical issues as of November 2019: (1) The Trump adm
2022-03-25 09:34:00 Friday ET
Corporate cash management The empirical corporate finance literature suggests four primary motives for firms to hold cash. These motives include the tra
2019-06-09 11:29:00 Sunday ET
St Louis Federal Reserve President James Bullard indicates that his ideal baseline scenario remains a mutually beneficial China-U.S. trade deal. Bullard ind